



FILE NO. A32759 070165.0555
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Wilson et al.

Serial No. : 09/478,737 Examiner: Murphy, J.

Filed : January 6, 2000 Group Art Unit: 1646

For : SCREENING METHODS FOR COMPOUNDS
USEFUL IN THE REGULATION OF
POLYCYSTIC KIDNEY DISEASE

RESPONSE TO RESTRICTION REQUIREMENT AND
SUBMISSION OF SEQUENCE LISTING

I hereby certify that this paper is being deposited with the United States
Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231

May 25, 2001
Date of Deposit

Carmella L. Stephens 41,328
Attorney Name PTO Registration No.

Carmella L. Stephens
Signature

May 25, 2001
Date of Signature

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement dated March 27, 2001,

Applicants elect, with traverse, to pursue the invention of Group I, namely Claims 1-10, in the instant application. Applicants request that non-elected Claims 11-20 be canceled without prejudice to the prosecution of the subject matter of non-elected claims in other patent applications. Together with this Response, Applicants also enclose a Petition for

Extension of Time for One Month (37 CFR 1.136(a)), up to and including May 27, 2001.

The extension fee of \$110.00 is enclosed.

Further, also in response to the Office Action of March 27, 2001, pursuant to 37 C.F.R. § 1.821-1.825, respectively, Applicants submit herewith a Sequence Listing in paper and computer readable form. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same. A copy of the Notice to Comply is attached. If any fees are associated with submission of the Sequence Listing, please charge Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

Respectfully submitted,

Carmella L. Stephens
Richard S. Clark
Patent Office Reg. No. 26,154
Attorney for Applicant

Carmella L. Stephens
Patent Office Reg. No. 41,328
Agent for Applicant

Baker Botts L.L.P.
30 Rockefeller Plaza
New York, NY 10112

(212) 408-2539



Application No.: 09/4787

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: _____

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE